Cargando…

Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides

PURPOSE: Cholecystokinin 2 (CCK-2) receptor overexpression has been demonstrated in various tumours such as medullary thyroid carcinomas and small-cell lung cancers. Due to this high expression, CCK-2 receptors might be suitable targets for radionuclide imaging and/or radionuclide therapy. Several C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laverman, Peter, Joosten, Lieke, Eek, Annemarie, Roosenburg, Susan, Peitl, Petra Kolenc, Maina, Theodosia, Mäcke, Helmut, Aloj, Luigi, von Guggenberg, Elisabeth, Sosabowski, Jane K., de Jong, Marion, Reubi, Jean-Claude, Oyen, Wim J. G., Boerman, Otto C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3127012/ https://www.ncbi.nlm.nih.gov/pubmed/21461732 http://dx.doi.org/10.1007/s00259-011-1806-0

Ejemplares similares

Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors
por: Roosenburg, Susan, et al.
Publicado: (2010)

Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients
por: Maina, Theodosia, et al.
Publicado: (2016)

Therapeutic application of CCK2R-targeting PP-F11: influence of particle range, activity and peptide amount
por: Konijnenberg, Mark W, et al.
Publicado: (2014)

Evaluation of CCK2 receptor binding ligands: the inheritance of Thomas Behr
por: Boerman, Otto C., et al.
Publicado: (2011)

A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study
por: Erba, Paola A., et al.
Publicado: (2018)

Effect of N-Terminal Peptide Modifications on In Vitro and In Vivo Properties of (177)Lu-Labeled Peptide Analogs Targeting CCK2R
por: Hörmann, Anton Amadeus, et al.
Publicado: (2023)

Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo
por: Ashurst, H Louise, et al.
Publicado: (2008)

Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with (111)In in HEPES and MES buffer
por: Brom, Maarten, et al.
Publicado: (2012)

The Role of Gastrin and CCK Receptors in Pancreatic Cancer and other Malignancies
por: Smith, Jill P., et al.
Publicado: (2016)

Radiolabelled peptides for oncological diagnosis
por: Laverman, Peter, et al.
Publicado: (2012)

Abnormal gastric morphology and function in CCK-B/gastrin receptor-deficient mice.
por: Rindi, G., et al.
Publicado: (1998)

Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice
por: Vegt, Erik, et al.
Publicado: (2010)

(111)In-exendin Uptake in the Pancreas Correlates With the β-Cell Mass and Not With the α-Cell Mass
por: Brom, Maarten, et al.
Publicado: (2015)

From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
por: Pawlak, Dariusz, et al.
Publicado: (2016)

Characterization of (111)In-labeled Glucose-Dependent Insulinotropic Polypeptide as a Radiotracer for Neuroendocrine Tumors
por: Willekens, Stefanie M. A., et al.
Publicado: (2018)

Exploiting the Concept of Multivalency with (68)Ga- and (89)Zr-Labelled Fusarinine C-Minigastrin Bioconjugates for Targeting CCK2R Expression
por: Summer, Dominik, et al.
Publicado: (2018)

[(111)In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study
por: Tatsi, Aikaterini, et al.
Publicado: (2012)

Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
por: Kolenc Peitl, Petra, et al.
Publicado: (2019)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
por: Asmar, Ali, et al.
Publicado: (2020)

CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours
por: Körner, Meike, et al.
Publicado: (2010)

Gastrin/CCK-B Receptor Signaling Promotes Cell Invasion and Metastasis by Upregulating MMP-2 and VEGF Expression in Gastric Cancer
por: Zhao, Yan, et al.
Publicado: (2022)

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics
por: Abouzayed, Ayman, et al.
Publicado: (2023)

Overexpression of Gastrin-Releasing Peptide Receptors in Tumor-Associated Blood Vessels of Human Ovarian Neoplasms
por: Fleischmann, Achim, et al.
Publicado: (2007)

Optimized labeling of NOTA-conjugated octreotide with F-18
por: Laverman, Peter, et al.
Publicado: (2011)

(68)Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET
por: Brom, Maarten, et al.
Publicado: (2010)

Peptide Radioligands in Cancer Theranostics: Agonists and Antagonists
por: Nock, Berthold A., et al.
Publicado: (2023)

Nonpeptidic Z360-Analogs Tagged with Trivalent Radiometals as Anti-CCK(2)R Cancer Theranostic Agents: A Preclinical Study
por: Nock, Berthold A., et al.
Publicado: (2022)

Cholecystokinin (CCK) and its receptors (CCK1R and CCK2R) in chickens: functional analysis and tissue expression
por: Wan, Yiping, et al.
Publicado: (2022)

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
por: Fröberg, Alida C., et al.
Publicado: (2009)

Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting
por: Verona, Marco, et al.
Publicado: (2021)

Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor
por: Pritchard, D. M., et al.
Publicado: (2008)

Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177
por: Hörmann, Anton Amadeus, et al.
Publicado: (2020)

(99m)Tc-labelled Stealth® liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
por: Laverman, P, et al.
Publicado: (2002)

Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials
por: Chau, I, et al.
Publicado: (2006)

Non-invasive in vivo determination of viable islet graft volume by (111)In-exendin-3
por: Eter, Wael A., et al.
Publicado: (2017)

Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides
por: Vegt, Erik, et al.
Publicado: (2009)

Correlation between radioactivity and chemotherapeutics of the (111)In-VNB-liposome in pharmacokinetics and biodistribution in rats
por: Lee, Wen-Chuan, et al.
Publicado: (2012)

Comparing Gly(11)/dAla(11)-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the (111)In-SB3/(111)In-SB4 Radiotracer Pair
por: Lymperis, Emmanouil, et al.
Publicado: (2019)

CCK2 receptors in chronic pain
por: LaVigne, Justin E., et al.
Publicado: (2022)

CCK reduces the food intake mainly through CCK1R in Siberian sturgeon (Acipenser baerii Brandt)
por: Zhang, Xin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i67kbfoas5rdra311bhjeorbbs